Quality vs. Margins | Discover how Dexcom's quality enhancement initiatives create near-term profitability pressures while potentially building long-term competitive advantages |
Competitive Battlefield | Intensifying rivalry in Type 1 and intensive Type 2 diabetes markets threatens market share as new entrants and established players introduce alternative solutions |
Analyst Targets | Price targets range from $71 to $80, reflecting mixed analyst sentiment on the company's ability to navigate competitive pressures and margin challenges |
Q4 Performance Shines | Dexcom exceeded Q4 sales and earnings expectations, demonstrating operational strength in diabetes management technology despite market uncertainties |

Metrics to compare | DXCM | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipDXCMPeersSector | |
|---|---|---|---|---|
P/E Ratio | 30.1x | 22.0x | −0.4x | |
PEG Ratio | 0.40 | −0.80 | 0.00 | |
Price / Book | 9.5x | 2.3x | 2.6x | |
Price / LTM Sales | 5.8x | 2.7x | 3.0x | |
Upside (Analyst Target) | 17.3% | 48.9% | 58.1% | |
Fair Value Upside | Unlock | 5.3% | 8.2% | Unlock |
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.